Circassia announces results from ToleroMune cat allergy phase II clinical study

Published on February 25, 2013 at 7:24 AM · No Comments

Commenting on the results, co-author of the AAAAI conference presentation, Professor Mark Larché , Canada Research Chair in Allergy and Immune Tolerance, McMaster University and St. Joseph's Healthcare, Hamilton, said, "Sustaining such a substantial improvement in patients' allergy symptoms two years after the start of the study is remarkable.  Achieving this with a short course of just four doses is even more impressive.  These results suggest that ToleroMune® therapy has the potential to revolutionise treatment for cat allergy patients."

"These excellent clinical results are extremely encouraging, and strongly support Circassia's decision to progress to phase III at the end of last year," said Steve Harris , Circassia's CEO.  "Offering patients sustained symptom control without the need for ongoing treatment is an important objective for allergy therapy.  In this study, our ToleroMune® treatment reduced symptoms by two and a half to three times the level achieved by several other allergy therapies in similar studies, and maintained the improvement over a significant period, demonstrating its potential to greatly improve the lives of patients around the world."

SOURCE Circassia

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post